Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
iloprost · 3 trials · 3 indications
Number of adverse events
Number of serious adverse events
Number of adverse events leading to discontinuation of study treatment
Number of patients with adverse events leading to discontinuation of study treatment
The 6-minute walk test was performed 20-40 minutes after treatment. This was a non-encouraged test (the person conducting the test did not encourage the patient to walk farther or faster) that measured the distance covered over a 6-minute walk. It was conducted by a trained member of the site staff who was listed on the site's delegation of authority sheet. For patients who had never performed a 6-minute walk test previously, a training test was requested before the qualifying tests for randomization.
| Arm | Type | Description |
|---|---|---|
| iloprost power 6 | ACTIVE_COMPARATOR | iloprost power 15 |
| iloprost power 15 | EXPERIMENTAL | iloprost power 15 |
| Active / placebo | EXPERIMENTAL | Single dose of iloprost (5 µg) on study day 2 followed by single dose of placebo on study day 3 |
| Placebo / active | PLACEBO_COMPARATOR | Single dose of placebo on study day 2 followed by single dose of iloprost (5 µg) on study day 3 |
| Name | Type | Description |
|---|---|---|
| iloprost | DRUG | Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study. |
| iloprost (5 µg) | DRUG | Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc |
| placebo | DRUG | Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc |
| Iloprost Inhalation Solution (Ventavis) | DRUG | - |
Inclusion Criteria: 1. Signed informed consent prior to initiation of any study mandated procedure, 2. Patients with symptomatic idiopathic or familial pulmonary arterial hypertension in NYHA functional class II to IV who have completed study AC-063A301, 3. Women of childbearing potential must have...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
Iloprost is a small molecule being studied for pulmonary fibrosis and pulmonary arterial hypertension. It is an investigational drug in clinical development, and it is not approved for these uses. Clinical trials have evaluated inhaled iloprost in adults with abnormal pulmonary pressure associated with idiopathic pulmonary fibrosis.
Iloprost is a prostacyclin analog that works by relaxing blood vessels and reducing pressure in the pulmonary arteries. It is being studied for conditions involving abnormal pulmonary pressure, such as pulmonary fibrosis and pulmonary arterial hypertension.
Iloprost is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 2 clinical development for pulmonary fibrosis and pulmonary arterial hypertension.
Iloprost is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Clinical trials have been completed for its use in pulmonary fibrosis and pulmonary arterial hypertension.
Iloprost has been studied in clinical trials including NCT00109681, which evaluated inhaled iloprost in adults with abnormal pulmonary pressure associated with idiopathic pulmonary fibrosis, and NCT00709098 and NCT00709956, which studied Iloprost Power 15 in pulmonary arterial hypertension. These trials have been completed.
Iloprost Power 15 is a formulation of Iloprost that has been studied in clinical trials for pulmonary arterial hypertension. The trials NCT00709098 and NCT00709956 evaluated this specific formulation in patients with the condition.